Allogeneic Transplantation From Related Haploidentical Donors

PHASE2CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

August 31, 2000

Primary Completion Date

December 31, 2010

Study Completion Date

December 31, 2010

Conditions
Blood CancerLeukemiaGraft Versus Host DiseaseMalignancyCLLNHLHodgkin's DiseaseMDS
Interventions
PROCEDURE

non-myeloablative hematopoietic cell transplantation

TLI and ATG infusion of the donor graft Post-transplant immunosuppression with cyclosporine and mycophenolate mofetil.

DRUG

Anti-Thymocyte Globulin

1.5 mg/kg QD x 5, IV. Dosage will be based on body weight. Purified, sterile IgG fraction of immune serum of rabbits immumixied with human thymus lymphocyte. This drug acts to modify the number and function of lymphocytes.

DRUG

Cyclosporine

6.25 mg/kg BID, PO.Mechanism of action is inhibition of T-cell activation by binding to a cytoplasmic protein (cyclophillin).

DRUG

Mycophenolate Mofetil

15 mg/kg Q 8 hours, PO. Inhibtis the enzme inosine monophsophate dehydrogenase (MPDII) noncompetitively which blocks the de nobo synthesis of guanosine required for DNA synthesis and has an effect on T and B cells.

DRUG

G-CSF

16 mg/kg, SQ Growth factor used to make bone marrow produce more blood cells

DRUG

Solumedrol

1.0 mg/kg IV 2 hours prior to ATG Used to treat severe inflamation

DRUG

Acetaminophen

650 mg PO, 30 minutes prior to infusion Pain reliever

DRUG

Diphenydramine

50 mg IV, 30 minutes prior to infusion Used to relieve allergy symptoms

DRUG

Hydrocortisone

100 mg IV, 1 hour prior to infusion Used to relieve itching, redness and swelling of the skin

Trial Locations (1)

94305

Stanford University School of Medicine, Stanford

All Listed Sponsors
lead

Stanford University

OTHER

NCT00185692 - Allogeneic Transplantation From Related Haploidentical Donors | Biotech Hunter | Biotech Hunter